
Sign up to save your podcasts
Or


The Science Behind The Psychedelics Boom
There’s been an explosion of new research into therapeutic uses for psychedelics. This includes drugs like psilocybin, the hallucinogenic chemical found in “magic mushrooms,” and ketamine—which was originally used as an anesthetic, and later became a popular party drug also known as “special K.”
Esketamine, a form of ketamine, was approved by the FDA in 2019 for use in treatment resistant depression. And just last month Colorado residents voted to legalize medicinal use of psilocybin. Following on the heels of Oregon’s legalization in 2020, which is now in the process of being implemented.
A recent study published in the New England Journal of Medicine showed promising results in using psilocybin to help patients with treatment-resistant depression. About a third of those who received the highest dose were in remission 3 weeks later. This was the largest look at psilocybin’s effect on depression to date, involving 233 participants across ten countries in Europe.
Ira talks with Dr. Steve Levine, senior vice president of patient access and medical affairs at COMPASS Pathways, the company that funded the study.
Later, Ira takes a closer look into the latest psychedelic research and takes listener calls with Dr. Gerard Sanacora, professor of psychiatry and director of the Yale Depression Research Program at the Yale School of Medicine, and Dr. Alissa Bazinet, Clinical Psychologist, Co-Founder and Director of Research and Development at the Sequoia Center, and Associate Director of the Social Neuroscience and Psychotherapy Lab at Oregon Health and Science University.
Back in August, controversy erupted around the winning submission of the Colorado State Fair’s art content. The winning painting wasn’t made by a human, but by an artificial intelligence app called Midjourney, which takes text prompts and turns them into striking imagery, with the help of a neural network and an enormous database of images.
AI-based text-to-image generators have been around for years, but their outputs were rudimentary and rough. The State Fair work showed this technology had taken a giant leap forward in its sophistication. Realistic, near-instant image generation was suddenly here—and reactions were just as potent as their creations.
Tech enthusiasts lauded the achievement, while artists were largely concerned and critical. If anyone could make a painting in just a few seconds, why would someone need to commission an artist to produce an illustration, or even bother spending years learning art at all?
Read the rest on sciencefriday.com.
Transcripts for each segment will be available the week after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
By Science Friday and WNYC Studios4.4
58945,894 ratings
The Science Behind The Psychedelics Boom
There’s been an explosion of new research into therapeutic uses for psychedelics. This includes drugs like psilocybin, the hallucinogenic chemical found in “magic mushrooms,” and ketamine—which was originally used as an anesthetic, and later became a popular party drug also known as “special K.”
Esketamine, a form of ketamine, was approved by the FDA in 2019 for use in treatment resistant depression. And just last month Colorado residents voted to legalize medicinal use of psilocybin. Following on the heels of Oregon’s legalization in 2020, which is now in the process of being implemented.
A recent study published in the New England Journal of Medicine showed promising results in using psilocybin to help patients with treatment-resistant depression. About a third of those who received the highest dose were in remission 3 weeks later. This was the largest look at psilocybin’s effect on depression to date, involving 233 participants across ten countries in Europe.
Ira talks with Dr. Steve Levine, senior vice president of patient access and medical affairs at COMPASS Pathways, the company that funded the study.
Later, Ira takes a closer look into the latest psychedelic research and takes listener calls with Dr. Gerard Sanacora, professor of psychiatry and director of the Yale Depression Research Program at the Yale School of Medicine, and Dr. Alissa Bazinet, Clinical Psychologist, Co-Founder and Director of Research and Development at the Sequoia Center, and Associate Director of the Social Neuroscience and Psychotherapy Lab at Oregon Health and Science University.
Back in August, controversy erupted around the winning submission of the Colorado State Fair’s art content. The winning painting wasn’t made by a human, but by an artificial intelligence app called Midjourney, which takes text prompts and turns them into striking imagery, with the help of a neural network and an enormous database of images.
AI-based text-to-image generators have been around for years, but their outputs were rudimentary and rough. The State Fair work showed this technology had taken a giant leap forward in its sophistication. Realistic, near-instant image generation was suddenly here—and reactions were just as potent as their creations.
Tech enthusiasts lauded the achievement, while artists were largely concerned and critical. If anyone could make a painting in just a few seconds, why would someone need to commission an artist to produce an illustration, or even bother spending years learning art at all?
Read the rest on sciencefriday.com.
Transcripts for each segment will be available the week after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

91,032 Listeners

21,983 Listeners

43,979 Listeners

32,111 Listeners

38,477 Listeners

30,667 Listeners

43,709 Listeners

38,727 Listeners

9,197 Listeners

1,571 Listeners

470 Listeners

941 Listeners

12,724 Listeners

14,457 Listeners

12,173 Listeners

822 Listeners

1,543 Listeners

3,511 Listeners

2,800 Listeners

1,400 Listeners

1,196 Listeners

5,570 Listeners

5,772 Listeners

421 Listeners

16,240 Listeners

6,421 Listeners

2,822 Listeners

2,316 Listeners

643 Listeners

1,962 Listeners

106 Listeners

20 Listeners

9 Listeners